Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial

IMPORTANCE: The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown. OBJECTIVE: To confirm the safety and efficacy of bimagrumab plus the new standard of care on skeletal muscle mass, strength,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rooks, Daniel, Swan, Therese, Goswami, Budhaditya, Filosa, Lee Anne, Bunte, Ola, Panchaud, Nicolas, Coleman, Laura A., Miller, Ram R., Garcia Garayoa, Elisa, Praestgaard, Jens, Perry, Robert G., Recknor, Chris, Fogarty, Charles M., Arai, Hidenori, Chen, Liang-Kung, Hashimoto, Jun, Chung, Yoon-Sok, Vissing, John, Laurent, Didier, Petricoul, Olivier, Hemsley, Sarah, Lach-Trifilieff, Estelle, Papanicolaou, Dimitris A., Roubenoff, Ronenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573681/
https://www.ncbi.nlm.nih.gov/pubmed/33074327
http://dx.doi.org/10.1001/jamanetworkopen.2020.20836

Ejemplares similares

Ejemplares similares